e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Cellular and molecular aspects of pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Imbalanced type I TGF-β receptor signalling in the pulmonary vasculature: implications for the pathogenesis of bronchopulmonary dysplasia
M. Michiels-Corsten, A. Kumarasamy, M. Wygrecka, B. Eul, W. Seeger, O. Eickelberg, R. Morty (Giessen, Germany)
Source:
Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Session:
Cellular and molecular aspects of pulmonary hypertension
Session type:
Electronic Poster Discussion
Number:
488
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Michiels-Corsten, A. Kumarasamy, M. Wygrecka, B. Eul, W. Seeger, O. Eickelberg, R. Morty (Giessen, Germany). Imbalanced type I TGF-β receptor signalling in the pulmonary vasculature: implications for the pathogenesis of bronchopulmonary dysplasia. Eur Respir J 2007; 30: Suppl. 51, 488
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Aerosolized IL-1β receptor antgonist: potential prevention of bronchopulmonary dysplasia?
Source: Eur Respir J 2006; 28: Suppl. 50, 361s
Year: 2006
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension
Source: Eur Respir J 2016; 48: 470-483
Year: 2016
Low telomerase expression in alveolar epithelial plays a role in the pathogenesis of idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
Increased pulmonary Wnt signaling in patients with sarcoidosis
Source: Annual Congress 2007 - Interstitial lung disease: diagnostic and therapeutic novelties
Year: 2007
Dysregulation of the TGF-beta system in idiopathic pulmonary fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 10s
Year: 2004
Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 459s
Year: 2003
Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia
Source: Eur Respir J, 59 (2) 2002248; 10.1183/13993003.02248-2020
Year: 2022
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Altered expression of the Smad signalling pathway: implications for COPD pathogenesis
Source: Eur Respir J 2006; 28: 533-541
Year: 2006
LATE-BREAKING ABSTRACT: Retinoids modulate TGF-β signalling in the lung through betaglycan and SMAD3: implications for retinoid use in bronchopulmonary dysplasia
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
The lung epithelium is a prominent source of Wnt ligands and inhibitors in idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Vascular and interstitial remodelling in chronic lung disease: therapeutic interventions on the horizon
Year: 2008
Contribution of angiopoietin/Tie2 pathway to pulmonary artery smooth muscle hyperplasia in idiopathic pulmonary hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Increased endothelial and epithelial apoptosis play a central role in the pathogenesis of systemic sclerosis and idiopathic pulmonary fibrosis
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Reactivation of developmental pathways in idiopathic pulmonary fibrosis: FGF9 and FGF18 modulate the phenotype of control and fibrotic human lung fibroblasts in vitro
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (5) 2000653; 10.1183/13993003.00653-2020
Year: 2021
Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 29 (158) 190140; 10.1183/16000617.0140-2019
Year: 2020
Involvement of the CD40-CD154 interaction in the regulation of surfactant production and development of secondary pulmonary alveolar proteinosis
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
Protease-activated receptor-2 triggers epithelial to mesenchymal transition: Potential relevance in pulmonary fibrosis
Source: Annual Congress 2011 - The ageing pulmonary interstitium
Year: 2011
Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2012; 21: 152-160
Year: 2012
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept